Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
HM
heather mckenzie
via Biospace
Updated 2h ago
Source Verification
Corroboration Score: 1This story was independently reported by 1 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
Inch 4K+ Programming Monitor Helps Reduce Eye Strain
Next
King Seiko Updates the Vanac in Titanium
Related Articles
HealthEledon Pharma FY25 Net Loss Widens; Tegoprubart Phase 3 Development On Track In Kidney Transplant
Unknown-4h ago-1 sources
HealthOil Prices Edge Higher After Drone Attack Targeting Kuwait Oil Refinery
Unknown-4h ago-2 sources
HealthTUHU Car Inc. Reveals Fall In Full Year Profit
Unknown-4h ago-1 sources